The city of Ann Arbor, Michigan, currently has 7 active clinical trials seeking participants for Dementia research studies.
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: University of Michigan, Ann Arbor, Ann Arbor, Michigan
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
All
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, Michigan +1 locations
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Stimulation of Cingulo-opercular Alertness Network
Recruiting
Fluctuations in alertness are very common in persons with Lewy body dementias and are a major source of disability. Changes in a chemical messenger molecule called acetylcholine within certain brain regions may play a role in these fluctuations. We propose to test this hypothesis and also determine whether a non-invasive way of stimulating affected brain regions may be of relevance for future management of these fluctuations.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/14/2024
Locations: 4251 Plymouth Road (University of Michigan), Ann Arbor, Michigan
Conditions: Lewy Body Disease, Lewy Body Variant of Alzheimer Disease, Lewy Body Dementia With Behavioral Disturbance
Stimulation to Improve Memory
Recruiting
This study will test the effects of different doses of a form of non-invasive brain stimulation for the treatment of individuals with mild cognitive impairment (MCI) and dementia of the Alzheimer's Type (DAT).
Gender:
All
Ages:
55 years and above
Trial Updated:
05/14/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Mild Cognitive Impairment, Dementia of Alzheimer Type
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
A Diagnostic Test for Dementia With Lewy Bodies
Recruiting
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/06/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
Natural History Study of Synucleinopathies
Recruiting
Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder, Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Shy-Drager Disease